A Study to Evaluate the Immunogenicity of Quadrivalent LAIV in Adults 18 to 49 Years of Age (MI-CP185)

This study has been completed.
Sponsor:
Information provided by:
MedImmune LLC
ClinicalTrials.gov Identifier:
NCT00860067
First received: March 9, 2009
Last updated: November 30, 2011
Last verified: November 2011
  Purpose

The objective of this study was to show that quadrivalent live attenuated influenza vaccine (Q/LAIV; MEDI3250) produced antibody levels similar to those produced by the commercial vaccine, FluMist.


Condition Intervention Phase
Healthy or Stable Underlying Chronic Medical Condition
Biological: Q/LAIV (MEDI3250)
Biological: FluMist/B/Yamagata
Biological: FluMist/B/Victoria
Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Bio-equivalence Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Randomized, Double-Blind, Active Controlled Study to Evaluate the Immunogenicity of MEDI3250 in Adults 18 to 49 Years of Age

Resource links provided by NLM:


Further study details as provided by MedImmune LLC:

Primary Outcome Measures:
  • The 4 Post-dose Strain-specific Serum Hemagglutination Inhibition (HAI) Antibody Geometric Mean Titers (GMT) in the Q/LAIV (MEDI3250) Arm Are Noninferior to Those in the Comparator FluMist Group. [ Time Frame: Day 28-35 ] [ Designated as safety issue: No ]
    Noninferior immune response was defined as having the upper bound of the 2-sided 95% confidence intervals (CIs) for the HAI antibody GMT ratio (FluMist comparator divided by Q/LAIV) ≤ 1.5 for each of the 4 strains.


Secondary Outcome Measures:
  • The Number of Participants (Regardless of Serostatus) Within Each Treatment Arm Who Experience Strain-specific Seroresponse Post Dose. [ Time Frame: Day 0 and Day 28-35 ] [ Designated as safety issue: No ]
    Seroresponse was defined as a ≥ 4-fold rise in HAI titer from baseline.

  • The Number of Serosusceptible Participants Within Each Treatment Arm Who Experience A/H1N1 Strain-specific Seroresponse Post Dose. [ Time Frame: Day 0 and Day 28-35 ] [ Designated as safety issue: No ]
    Seroresponse was defined as a ≥ 4-fold rise in HAI titer from baseline. Participants with a baseline HAI titer <= 8 were considered to be serosusceptible for that strain.

  • The Number of Serosusceptible Participants Within Each Treatment Arm Who Experience A/H3N2 Strain-specific Seroresponse Post Dose. [ Time Frame: Day 0 and Day 28-35 ] [ Designated as safety issue: No ]
    Seroresponse was defined as a ≥ 4-fold rise in HAI titer from baseline. Participants with a baseline HAI titer <= 8 were considered to be serosusceptible for that strain.

  • The Number of Serosusceptible Participants Within Each Treatment Arm Who Experience B/Yamagata Strain-specific Seroresponse Post Dose. [ Time Frame: Day 0 and Day 28-35 ] [ Designated as safety issue: No ]
    Seroresponse was defined as a ≥ 4-fold rise in HAI titer from baseline. Participants with a baseline HAI titer <= 8 were considered to be serosusceptible for that strain.

  • The Number of Serosusceptible Participants Within Each Treatment Arm Who Experience B/Victoria Strain-specific Seroresponse Post Dose. [ Time Frame: Day 0 and Day 28-35 ] [ Designated as safety issue: No ]
    Seroresponse was defined as a ≥ 4-fold rise in HAI titer from baseline. Participants with a baseline HAI titer <= 8 were considered to be serosusceptible for that strain.

  • The Number of Seropositive Participants Within Each Treatment Arm Who Experience A/H1N1 Strain-specific Seroresponse Post Dose. [ Time Frame: Day 0 and Day 28-35 ] [ Designated as safety issue: No ]
    Seroresponse was defined as a ≥ 4-fold rise in HAI titer from baseline. Participants with a baseline HAI titer > 8 were considered to be seropositive for that strain.

  • The Number of Seropositive Participants Within Each Treatment Arm Who Experience A/H3N2 Strain-specific Seroresponse Post Dose. [ Time Frame: Day 0 and Day 28-35 ] [ Designated as safety issue: No ]
    Seroresponse was defined as a ≥ 4-fold rise in HAI titer from baseline. Participants with a baseline HAI titer > 8 were considered to be seropositive for that strain.

  • The Number of Seropositive Participants Within Each Treatment Arm Who Experience B/Yamagata Strain-specific Seroresponse Post Dose. [ Time Frame: Day 0 and Day 28-35 ] [ Designated as safety issue: No ]
    Seroresponse was defined as a ≥ 4-fold rise in HAI titer from baseline. Participants with a baseline HAI titer > 8 were considered to be seropositive for that strain.

  • The Number of Seropositive Participants Within Each Treatment Arm Who Experience B/Victoria Strain-specific Seroresponse Post Dose. [ Time Frame: Day 0 and Day 28-35 ] [ Designated as safety issue: No ]
    Seroresponse was defined as a ≥ 4-fold rise in HAI titer from baseline. Participants with a baseline HAI titer > 8 were considered to be seropositive for that strain.

  • The Number of Participants (Regardless of Serostatus) Within Each Treatment Arm Who Achieved a Strain-specific HAI Antibody Titer ≥ 32 Post Dose. [ Time Frame: Day 28-35 ] [ Designated as safety issue: No ]
  • The Number of Serosusceptible Participants Within Each Treatment Arm Who Achieved a A/H1N1 Strain-specific HAI Antibody Titer ≥ 32 Post Dose. [ Time Frame: Day 28-35 ] [ Designated as safety issue: No ]
    Participants with a strain-specific baseline HAI titer ≤ 8 were considered to be serosusceptible to that strain.

  • The Number of Serosusceptible Participants Within Each Treatment Arm Who Achieved a A/H3N2 Strain-specific HAI Antibody Titer ≥ 32 Post Dose. [ Time Frame: Day 28-35 ] [ Designated as safety issue: No ]
    Participants with a strain-specific baseline HAI titer ≤ 8 were considered to be serosusceptible to that strain.

  • The Number of Serosusceptible Participants Within Each Treatment Arm Who Achieved a B/Yamagata Strain-specific HAI Antibody Titer ≥ 32 Post Dose. [ Time Frame: Day 28-35 ] [ Designated as safety issue: No ]
    Participants with a strain-specific baseline HAI titer ≤ 8 were considered to be serosusceptible to that strain.

  • The Number of Serosusceptible Participants Within Each Treatment Arm Who Achieved a B/Victoria Strain-specific HAI Antibody Titer ≥ 32 Post Dose. [ Time Frame: Day 28-35 ] [ Designated as safety issue: No ]
    Participants with a strain-specific baseline HAI titer ≤ 8 were considered to be serosusceptible to that strain.

  • The Number of Seropositive Participants Within Each Treatment Arm Who Achieved a A/H1N1 Strain-specific HAI Antibody Titer ≥ 32 Post Dose. [ Time Frame: Day 28-35 ] [ Designated as safety issue: No ]
    Participants with a baseline HAI titer > 8 were considered to be seropositive for that strain.

  • The Number of Seropositive Participants Within Each Treatment Arm Who Achieved a A/H3N2 Strain-specific HAI Antibody Titer ≥ 32 Post Dose. [ Time Frame: Day 28-35 ] [ Designated as safety issue: No ]
    Participants with a baseline HAI titer > 8 were considered to be seropositive for that strain.

  • The Number of Seropositive Participants Within Each Treatment Arm Who Achieved a B/Yamagata Strain-specific HAI Antibody Titer ≥ 32 Post Dose. [ Time Frame: Day 28-35 ] [ Designated as safety issue: No ]
    Participants with a baseline HAI titer > 8 were considered to be seropositive for that strain.

  • The Number of Seropositive Participants Within Each Treatment Arm Who Achieved a B/Victoria Strain-specific HAI Antibody Titer ≥ 32 Post Dose. [ Time Frame: Day 28-35 ] [ Designated as safety issue: No ]
    Participants with a baseline HAI titer > 8 were considered to be seropositive for that strain.

  • The Number of Participants Experiencing Each Solicited Symptom From Administration of Investigational Product Through 14 Days Post Vaccination [ Time Frame: Days 0-14 ] [ Designated as safety issue: Yes ]
    Solicited symptoms were fever ≥ 100.4°F (38.0°C), runny/stuffy nose, sore throat, cough, headache, generalized muscle aches, decreased activity level (lethargy) OR tiredness/weakness, decreased appetite. Collection of specific solicited symptoms (sore throat, headache, generalized muscle aches) was omitted when, according to the judgment of the investigator, the subject was too young to reliably report a particular symptom.

  • The Number of Participants Reporting Any Adverse Event From Administration of Investigational Product Through 28 Days Post Vaccination [ Time Frame: Days 0-28 post vaccination ] [ Designated as safety issue: Yes ]
    Any untoward medical occurrence in a patient or clinical investigation in a subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product

  • Number of Participants Reporting Any Serious Adverse Event From Administration of Investigational Product Through 28 Days Post Vaccination [ Time Frame: Days 0-28 post vaccination ] [ Designated as safety issue: Yes ]
    Serious adverse events were those that resulted in death; were life-threatening; resulted in inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability or incapacity; were a birth defect in the offspring of a study participant; or were an important medical event that may not have resulted in death, threatened life, or required hospitalization but that, based on appropriate medical judgment, may have jeopardized the subject and may have required medical or surgical intervention to prevent one of the outcomes listed above.

  • Number of Participants Reporting Any Serious Adverse Event From Administration of Investigational Product Through 180 Days Post Vaccination [ Time Frame: Days 0-180 post vaccination ] [ Designated as safety issue: Yes ]
    Serious adverse events were those that resulted in death; were life-threatening; resulted in inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability or incapacity; were a birth defect in the offspring of a study participant; or were an important medical event that may not have resulted in death, threatened life, or required hospitalization but that, based on appropriate medical judgment, may have jeopardized the subject and may have required medical or surgical intervention to prevent one of the outcomes listed above.

  • Number of Participants Reporting New Onset Chronic Diseases From Administration of Investigational Product Through 180 Days Post Vaccination [ Time Frame: Days 0-180 post vaccination ] [ Designated as safety issue: Yes ]
    An NOCD was a newly diagnosed medical condition that was of a chronic, ongoing nature and was assessed by the investigator as medically significant.


Enrollment: 1800
Study Start Date: March 2009
Study Completion Date: October 2009
Primary Completion Date: May 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Q/LAIV (MEDI3250)
Q/LAIV (quadrivalent influenza vaccine) (MEDI3250) was supplied in the Becton Dickinson (BD) Accuspray device that delivers a 0.2 mL total volume intranasal dose divided into each nostril (ie, administered as 0.1 mL per nostril). Each 0.2 mL dose contained 10^7.0 ± 0.5 fluorescent focus units (FFU) of each of 4 temperature-sensitive, cold-adapted, attenuated, 6:2 reassortant influenza strains (A/H1N1 [A/South Dakota/6/2007], A/H3N2 [A/Uruguay/716/2007], B/Victoria [B/Malaysia/2506/2004], and B/Yamagata [B/Florida/4/2006]).
Biological: Q/LAIV (MEDI3250)
0.2 mL dose at Day 0
Other Name: MEDI3250
Active Comparator: FluMist/B/Yamagata
FluMist/B/Yamagata (trivalent influenza vaccine) was supplied in the BD Accuspray device that delivers a 0.2 mL total volume intranasal dose divided into each nostril (ie, administered as 0.1 mL per nostril). Each 0.2 mL dose contained 10^7.0 ± 0.5 FFU of each of 3 temperature-sensitive, cold-adapted, attentuated, 6:2 reassortant influenza strains (A/H1N1 [A/South Dakota/6/2007], A/H3N2 [A/Uruguay/716/2007], and B/Yamagata [B/Florida/4/2006])a B strain of the Yamagata lineage.
Biological: FluMist/B/Yamagata
0.2 mL dose at Day 0
Other Name: FluMist
Active Comparator: FluMist/B/Victoria
FluMist/B/Victoria(trivalent influenza vaccine) was supplied in the BD Accuspray device that delivers a 0.2 mL total volume intranasal dose divided into each nostril (ie, administered as 0.1 mL per nostril). Each 0.2 mL dose contained 10^7.0 ± 0.5 FFU of each of 3 temperature-sensitive, cold-adapted, attenuated, 6:2 reassortant influenza strains (A/H1N1 [A/South Dakota/6/2007], A/H3N2 [A/Uruguay/716/2007], and B/Victoria [B/Malaysia/2506/2004])a B strain of the Victoria lineage.
Biological: FluMist/B/Victoria
0.2 mL dose at Day 0
Other Name: FluMist

Detailed Description:

This randomized, double-blind, active controlled, multicenter study enrolled 1,800 subjects who were 18 to 49 years of age. Subjects were randomized by site in a 4:1:1 fashion to receive a single dose of Q/LAIV, trivalent FluMist containing an influenza B strain from the Yamagata lineage (FluMist/B/Yamagata), or trivalent FluMist containing an influenza B strain from the Victoria lineage (FluMist/B/Victoria). The study was conducted at multiple sites in the USA in the influenza off-season.

  Eligibility

Ages Eligible for Study:   18 Years to 49 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Male or female age 18 to 49 years, inclusive, on the day of randomization (reached his or her eighteenth year birthday but not yet reached his or her 50th year birthday) at the time of the dose of blinded investigational product
  • Written informed consent and any locally required authorization obtained from the subject prior to performing any protocol-related procedures, including screening evaluations
  • Females of child-bearing potential, (ie, unless surgically sterile [eg, bilateral tubal ligation, bilateral oophorectomy, or hysterectomy], had a sterile male partner, was at least 1 year post-menopausal, or practiced abstinence) must have used an effective method of avoiding pregnancy (including oral, transdermal, or implanted contraceptives, intrauterine device, female condom with spermicide, diaphragm with spermicide, cervical cap, or use of a condom with spermicide by the sexual partner) for 30 days prior to the first dose of investigational product, and must have agreed to continue using such precautions for 60 days after the dose of investigational product. In addition, the subject must also have had a negative urine or blood pregnancy test at screening and, if screening and Day 0 did not occur on the same day, on the day of vaccination prior to randomization. Investigator judgment was required to assess a female subject's capability of pregnancy.
  • Healthy by medical history and physical examination OR presence of stable underlying chronic medical condition for which hospitalization was not required in the previous year
  • Able to complete follow-up period of 180 days post dose of vaccine as required by the protocol
  • Subject available by telephone
  • Able to understand and comply with the requirements of the protocol, as judged by the investigator

Exclusion Criteria:

  • Acute illness or evidence of significant active infection at randomization
  • Fever ≥ 100.4°F (38°C) at randomization
  • History of asthma
  • Any drug therapy from 15 days prior to randomization or expected drug therapy through 30 days post dose with the exception of contraceptives or chronic medications that were well tolerated and were not initiated and/or did not have a dosage change within 90 days of randomization.
  • Previous medical history or evidence of an intercurrent illness that might have compromised the safety of the subject in the study
  • Current or expected receipt of immunosuppressive medications (inhaled and topical corticosteroids were permitted) including corticosteroids (≥ 20 mg/day of prednisone equivalent given daily or on alternate days for ≥ 14 days) within a 30-day window around dose of investigational product Note: topical corticosteroids for uncomplicated dermatitis were permitted according to the judgment of the investigator; topical calcineurin inhibitors were permitted in accordance with their package insert at entry and during study participation.
  • Receipt of immunoglobulin or blood products within 90 days before randomization into the study or expected receipt during study participation
  • Receipt of any investigational drug therapy or standard vaccine within 30 days before the dose of investigational product in this study through 30 days after the dose of investigational product (use of licensed agents for indications not listed in the package insert was permitted)
  • Any known immunosuppressive condition or immune deficiency disease including known or suspected infection with human immunodeficiency virus (HIV)
  • History of allergic disease or reactions likely to be exacerbated by any component of the investigational product including allergy to eggs, egg proteins, gentamicin, or gelatin; or serious, life threatening, or severe reactions to previous influenza vaccinations
  • History of Guillain-Barré syndrome
  • Use of antiviral agents with activity against influenza virus (including amantadine, rimantadine, oseltamivir and zanamivir) within 30 days prior to dose of investigational product or anticipated use within 30 days after vaccination
  • Known or suspected mitochondrial encephalomyopathy
  • Lactating woman
  • History of alcohol or drug abuse that, in the opinion of the investigator, would have affected the subject's safety or compliance with study
  • Any condition that, in the opinion of the investigator, would have interfered with evaluation of the investigational product or interpretation of subject safety or study results
  • Employees of the clinical study site or any other individuals involved with the conduct of the study, or immediate family members of such individuals
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00860067

Locations
United States, California
Benchmark Research
Sacramento, California, United States, 95816
California Research Foundation
San Diego, California, United States, 92103-6204
Benchmark Research
San Francisco, California, United States, 94102
United States, Florida
University Clinical Research-Deland, LLC
Deland, Florida, United States, 32720
Pharmax Research Clinic, Inc
Miami, Florida, United States, 33126
University Clinical Research, Inc
Pembroke Pines, Florida, United States, 33024
Miami Research Associates
South Miami, Florida, United States, 33143
United States, Georgia
Clinical Research Atlanta
Stockbridge, Georgia, United States, 32801
United States, Kansas
Vince and Associates Clinical Research
Overland Park, Kansas, United States, 66212
United States, Kentucky
Kentucky Pediatric / Adult Research
Bardstown, Kentucky, United States, 40004
United States, Missouri
The Center for Pharmaceutical Research, PC
Kansas City, Missouri, United States, 64114
Sundance Clinical Research
St. Louis, Missouri, United States, 63141
United States, Nebraska
Meridian Clinical Research, LLC
Omaha, Nebraska, United States, 68314
United States, New York
Rochester Clinical Research, Inc.
Rochester, New York, United States, 14609
United States, Tennessee
Clinical Research Associates, Inc
Nashville, Tennessee, United States, 37201
United States, Texas
Benchmark Research
Austin, Texas, United States, 78705
Benchmark Research
Ft. Worth, Texas, United States, 76135
United States, Utah
Advanced Clinical Research
West Jordan, Utah, United States, 84088
Sponsors and Collaborators
MedImmune LLC
Investigators
Study Director: Judith Falloon, M.D. MedImmune LLC
  More Information

Additional Information:
Publications:
Responsible Party: Judith Falloon, M.D., MedImmune, LLC an affiliate of AstraZeneca AB
ClinicalTrials.gov Identifier: NCT00860067     History of Changes
Other Study ID Numbers: MI-CP185
Study First Received: March 9, 2009
Results First Received: June 10, 2011
Last Updated: November 30, 2011
Health Authority: United States: Food and Drug Administration

Keywords provided by MedImmune LLC:
influenza, FluMist, adults, vaccine

ClinicalTrials.gov processed this record on August 21, 2014